Mubritinib
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H23F3N4O2 |
Molar mass | 468.480 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
References
- McCormick F, Fabbro D (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. doi:10.1385/1-59259-962-1:001. ISBN 1-58829-384-X.
- Mitscher LA, Lednicer D (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.
- Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
- Clinical trial number NCT00034281 for "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2" at ClinicalTrials.gov
CI monoclonal antibodies ("-mab") |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Tyrosine kinase inhibitors ("-nib") |
| ||||||||
Other |
|
Angiopoietin |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CNTF | |||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF |
| ||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) | |||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.